# US 2019/0134168 A1 · Combination, Therapeutic Uses And Prophylactic Uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0134168 A1
- Document ID: US20190134168A1
- Status: Published application
- Kind: A1
- Application number: 16/094,058
- Filed: 2017-04-21
- Published: 2019-05-09
- Earliest claimed: 2016-04-21
- Assignees: Quantec Limited
- Applicants: Quantec Limited
- Inventors: Judith Mary Bragger; Rodney Wayne Claycomb; Colin Roger Ogle
- Web page: https://patentgrep.com/patent/US20190134168A1

## CPC

- A61K 38/54: Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
- A61K 35/20: Milk; Whey; Colostrum
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/44: Oxidoreductases (1)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- C07K 16/04: from milk
- A61K 2039/505: {comprising antibodies}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to the therapeutic and prophylactic use of a combination including lactoperoxidase and at least one other component, with an isoelectric point of, or substantially above 6.8, and which are extracted from milk, to modulate the microbiome of an animal by selectively against at least one pathogenic microoganism.

## Claims

### Claim 1

A method of modulating a microbiome by selectively inhibiting growth or killing at least one pathogenic micro-organism without a comparative inhibition of at least one commensal micro-organism, the method comprising the step of administering to an animal a combination including
lactoperoxidase; and
at least one other component,
wherein the lactoperoxidase and at least one other component have an isoelectric point of or above 6.8 and which are extracted from milk.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the combination is a composition.

### Claim 3 (depends on 2)

The method according to claim 2 wherein the lactoperoxidase and at least one other component are in intimate admixture in the milk and remain in intimate admixture in the formation of the composition.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the combination is applied externally.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the combination is applied internally.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the at least one other component is independently selected from the group consisting of: lactoferrin; angiogenin; and lysozyme-like protein.

### Claim 7 (depends on 1)

The method Use according to claim 1 wherein the combination includes lactoperoxidase, lactoferrin, angiogenin, and lysozyme-like protein, all having an isoelectric point of or above 6.8 and which are extracted from milk.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the combination includes lactoperoxidase, lactoferrin, angiogenin, lysozyme-like protein, quiescin, and jacalin-like protein, all having an isoelectric point of or above 6.8 and which are extracted from milk.

### Claim 9 (depends on 1)

The method according to claim 1 wherein the combination includes proteins isolated from milk which have an isoelectric point of or above 6.8.

### Claim 10 (depends on 1)

The method according to claim 1 wherein the pathogenic micro-organism is selected from the group consisting of: Propionibacterium acnes, Trichophyton mentagrophytes, Trichophyton rubrum, Escherichia coli, Streptococcus pyogenes, Malassezia furfur, Candida albicans, Staphylococcus aureus and Streptococcus mutans.

### Claim 11 (depends on 1)

The method according to claim 1 wherein the commensal micro-organism is selected from the group consisting of: Staphylococcus epidermidis, Streptococcus pneumonia, Staphylococcus hominis, Lactobacillus bulgaricus, Lactobacillus casei, Porphyromonas gingivalis, Streptococcus mitis and Streptococcus salivarius.

### Claim 12 (depends on 1)

The method according to claim 1 wherein the combination further includes one or more components selected from the group consisting of: substrates; adjuvants; prebiotics; and probiotics.

### Claim 13 (depends on 1)

The method according to claim 1 wherein the combination further includes one or more components selected from the group consisting of: a peroxidase substrate; hydrogen peroxide or a source of hydrogen peroxide; and a cell-lysing substance capable of fully, or partially lysing cell walls.

### Claim 14 (depends on 1)

The method according to claim 1 wherein the combination further includes one or more components selected from the group consisting of: thiocyanate, ascorbate, glucose oxidase, glucose, and monolauryl glycerol.

### Claim 15 (depends on 1)

The method according to claim 1 wherein the combination further includes one or more components selected from the group consisting of: cathelicidin 1; N-acetyl glucosaminidase; serum amyloid A; β Defensin; Peptidoglycan recognition protein; Xanthine dehydrogenase; Immunoglobulin(s) (IgA, IgD, IgG, IgM, IgA, and/or IgE); and Growth factors (EGF, IGF 1, TGF B1 and TGF B2).

### Claim 16 (depends on 1)

The method according to claim 1 wherein the combination selectively inhibits growth of at least one pathogenic micro-organism by a multiple of at least 1.1 compared with a degree of inhibition of at least one commensal micro-organism.

### Claim 17

(canceled)

### Claim at position 18

18-25. (canceled)

### Claim 26 (depends on 1)

The method according to claim 1 wherein the at least one other component is angiogenin.

### Claim 27 (depends on 1)

The method according to claim 1 comprising at least 5% lactoperoxidase.

### Claim 28 (depends on 1)

The method according to claim 1 wherein the animal is a human.

### Claim 29 (depends on 1)

The method according to claim 1 wherein the pathogenic micro-organism is selected from the group consisting of Propionibacterium acnes, trichophyton mentagrophytes, Trichophyton rubrum, Streptococcus pyogenes, Malassezia furfur, Candidan albicans, and Streptococcus mutans.
